Quantcast

Latest Glioma Stories

2014-04-17 08:28:12

VISIUS intraoperative MRI significantly enhances amount of complete resection in brain tumors and leads to better patient outcomes MINNEAPOLIS, April 17, 2014 /PRNewswire/ - IMRIS Inc. (NASDAQ: IMRS; TSX: IM) ("IMRIS" or the "Company") today announced that a study published this month in the journal Neurosurgery by the neurosurgical team at Cleveland Clinic adds to growing clinical evidence which validates use of high-field intraoperative MRI (iMRI) as an effective tool for...

2014-04-11 08:24:10

CALGARY, April 11, 2014 /PRNewswire/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC) (NASDAQ:ONCY) today announced that Dr. Alan Melcher, Professor of Clinical Oncology and Biotherapy at the University of Leeds, presented at the 8(th) Annual International Conference on Oncolytic Virus Therapeutics held in Oxford, UK. Dr. Melcher's presentation, titled "Clinical Virotherapy and Immune Modulation; Bench to Bedside and Back Again," covered early clinical research showing that...

2014-04-10 08:29:39

Results Continue to Show Safety and Promising Survival; Program to Advance into a Randomized, Controlled Trial SAN DIEGO, April 10, 2014 /PRNewswire/ -- Tocagen Inc. today announced that updated interim clinical data from two ongoing investigational studies of Toca 511 in combination with Toca FC in 68 patients with recurrent high grade glioma were presented at the American Association of Neurological Surgeons (AANS) Annual Meeting in San Francisco. High grade gliomas include...

2014-04-09 12:31:10

VAL-083 therapy is well tolerated to date; dose limiting toxicity has not been reached after fifth cohort (20mg/m2) VANCOUVER, British Columbia and MENLO PARK, Calif., April 9, 2014 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar") today announced an update on its ongoing Phase I/II clinical trial with VAL-083 in the treatment of refractory glioblastoma multiforme (GBM). The company's new data are being presented in a poster entitled, "A Phase I/II Study of VAL-083 in...

2014-04-09 12:31:14

Three molecularly defined clusters could alter practice; 1 closely resembles deadly glioblastoma Comprehensive genomic analysis of low-grade brain tumors sorts them into three categories, one of which has the molecular hallmarks and shortened survival of glioblastoma multiforme, the most lethal of brain tumors, researchers reported at the American Association for Cancer Research Annual Meeting 2014. "The immediate clinical implication is that a group of patients with tumors previously...

2014-04-07 16:05:15

Researchers studying a rare, always fatal brain tumor in children have found several molecular alterations that drive the cancer, according to a new study from scientists at Dana-Farber/Boston Children's Cancer and Blood Disorders Center and McGill University. The findings identify potential new targets for drug treatments. The new research could help physicians choose targeted agents with a better chance of combating pediatric high-grade astrocytomas, which are extremely difficult to...

2014-03-19 23:22:34

Cancer patients with secondary brain tumors need information on diagnosis/treatment. Chicago, IL (PRWEB) March 19, 2014 As more effective cancer diagnostics and treatments are developed, and as larger numbers of cancer patients live longer, an increasing number are being diagnosed with metastatic brain tumors. To provide these patients and families with information on their diagnosis and treatment options, the American Brain Tumor Association (ABTA) is hosting a free webinar,...

2014-03-11 08:29:44

Intravenous Delivery Is An Important Advancement in the Development of Toca 511, Creates Opportunity For Use In Additional Cancer Indications SAN DIEGO, March 11, 2014 /PRNewswire/ -- Tocagen Inc. today announced that the first patient has been dosed in its clinical trial investigating the intravenous administration of selective cancer therapy Toca 511 & Toca FC, in patients with recurrent high grade glioma (HGG) including glioblastoma multiforme (GBM, Grade 4 HGG), the most...

2014-03-10 08:30:14

DCVax-L Is First Product of Its Kind to Receive Hospital Exemption from German Regulator BETHESDA, Md., March 10, 2014 /PRNewswire/ -- Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that it has received approval from the Paul Ehrlich Institute ("PEI"- the FDA of Germany) of a "Hospital Exemption" early access program under Section 4b of the German Drug Law. Under this...

New Imaging System Lights Up Tumors Using Scorpion Venom Protein And Laser
2014-02-26 10:42:27

Cedars-Sinai Medical Center Cedars-Sinai animal study may lead to human trial of experimental, compact intraoperative device to aid removal of malignant brain tumors Researchers at the Cedars-Sinai Maxine Dunitz Neurosurgical Institute and Department of Neurosurgery have developed a unique, compact, relatively inexpensive imaging device to "light up" malignant brain tumors and other cancers. The experimental system consists of a special camera designed and developed at Cedars-Sinai...


Word of the Day
mundungus
  • A stinking tobacco.
  • Offal; waste animal product; organic matter unfit for consumption.
This word comes from the Spanish 'mondongo,' tripe, entrails.